19 Jan 2016 | 09:13 am | 1 min. read
International law firm Pinsent Masons is celebrating being recognized for its commitment to workplace diversity in the 2016 Stonewall Workplace Equality Index.
Pinsent Masons has been ranked one of the top five most inclusive employers in the influential ranking which assesses the inclusivity of workplaces around the UK.
Pinsent Masons is the highest ranking law firm in this year’s Index and has also been ranked in Stonewall’s list of Global Diversity Champions for the first time.
David Isaac, Head of the Advanced Manufacturing and Technology sector and Chair of the Diversity Steering Group at Pinsent Masons, says:
“Pinsent Masons has worked hard to get into the top five of the Index and we are delighted to be the top ranking law firm. We were up against a lot of very tough competition so it’s an achievement that everyone in the firm should be exceedingly proud of.”
Pinsent Masons Senior Partner Richard Foley says:
“We are delighted with our ranking in this year’s Workplace Equality Index . Equality and diversity are critical foundations to our business and I am delighted that we have again been recognised by Stonewall for the work that we do. It is equally pleasing to see a number of other forward thinking law firms being recognised - this is an industry issue where we can and should be supporting and celebrating each other's achievements.”
For more information about the Stonewall Workplace Equality Index, go to www.stonewall.org.uk.
Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.
Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.
Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on